Population Genomic Screening in Primary Care Cooperative Agreement (U01 - Clinical Trial Required)
This Notice of Funding Opportunity (NOFO) solicits applications for Clinical Groups to be part of an implementation and evidence generation pilot program of population genomic screening for common, actionable genomic conditions predominantly in the primary care setting. This NOFO runs in parallel with companion NOFOs that invite applications for the Coordinating Center (RFA-HG-24-022) and the Sequencing Center (RFA-HG-24-023).
Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals with a potential for continued innovative and impactful research and combine their existing investigator-initiated studies into a single award to support the majority of their independent environmental health sciences research program.
Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to develop multi-organ automated microphysiological systems (MPS) for studying the effects of microgravity conditions on human body in low Earth orbit at the International Space Station National Laboratory (ISS-NL). This program will provide insights on human patho(physiology), especially aging-related functional decline and age-related diseases. The multi-organ MPS configuration will allow better modeling of the whole organism. Improved automation with extended longevity of MPS will facilitate longer experiments in space and the collection of more physiologically relevant data. The inclusion of samples representing the broad spectrum of diversity in the human population will allow for better modeling of aging progression and development of interventions. Funds from the NIH will be made available through the UG3/UH3 cooperative agreement mechanism. During the initial UG3 phase, support will be provided to develop robust complex organ systems, which can manifest the hallmarks of human age-related tissue and organ dysfunction and recapitulate the progression of aging-associated diseases when exposed to prolonged microgravity. The multi-organ integrated systems will be validated and tested on the ground to assess capability of chips to sustain flight-related stresses and to provide evidence of the functional utility of the proposed models for experiments at the ISS-NL. Following administrative review, the UH3 phase will build upon successful UG3-developed models to facilitate the assessment on the ISS-NL of the hallmarks of aging, biomarkers of associated diseases, bioavailability, efficacy, and toxicity of therapeutic agents. It is anticipated that these studies will lead to the identification of novel treatment mechanisms through better understanding of age-related disease biology, pathways and mechanisms underlying age-related tissue and organ functional decline and age-related diseases, drug screening, assessment of candidate therapies for efficacy and safety. This program will establish the pre-clinical foundation to inform clinical studies on Earth.
Polycystic Kidney Disease Core Centers (U54 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) requests applications for Polycystic Kidney Disease (PKD) Core Centers that are designed to support and enhance the national research effort in PKD through developing and broadly sharing innovative research tools and resources (e.g., reagents, data, services, and expertise that would be difficult or impractical to support by individual research project grants or within individual laboratories. The PKD Core Centers are expected to work collaboratively with the Central Coordinating Site as part of a national PKD Research Resource Consortium (PKD RRC).
This NOFO is open to new applications and renewals.
Women's Reproductive Health Research (WRHR) Career Development Program (K12 Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity announcement (NOFO) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to announce the re-competition of the Women’s Reproductive Health Research (WRHR) Career Development Program. This nationwide group of mentored institutional career development programs trains junior faculty who have recently completed postgraduate clinical training in obstetrics and gynecology and are committed to an independent research career in women's reproductive health. The goal of this program is to continue to build the national capacity of outstanding junior clinician-investigators who will strengthen the field of obstetrics and gynecology and contribute to the improvement of women’s health.
This Notice of Funding Opportunity (NOFO) allows appointment of [Scholars (K12)] proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) invites U01 applications from clinical centers (CCs) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC) to contribute to ongoing and new studies on chronic pancreatitis, both in children and adults. The consortium will continue the work of the current Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). The consortium has been renamed to reflect the revised research focus as described below.
The CPDPC since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, diabetes, and pancreatic cancer association. The CPDPC is composed of multiple Clinical Centers (CC) and one Data Coordinating Center (DCC). The continuation of the CPDPC, the CPCRC, will focus on chronic pancreatitis, both adults and children, to pursue and expand the objectives of the former consortium in these areas.
Applications for the data coordinating center are being invited via RFA-DK-25-020 “Single Source for the NIDDK Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC- DCC) (U01 Clinical Trial Optional).”
The DCC along with CCs share results freely within Consortium and will continue with collaborative projects that make use of the combined expertise and technological capabilities present in all the Consortium member institutions.
In addition, a major collaborative effort within the Consortium is the establishment of an annotated repository of bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue), administered by the DCC, to allow for the identification and validation of biomarkers for risk stratification and disease progression.
To effectively contribute to the ongoing CPDPC clinical studies, each CC application should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the ongoing consortium CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html) and the new CPCRC. All CCs share results freely within Consortium and to develop Consortium-wide collaborative projects that make use of the combined expertise and technological capabilities present in all the CCs.
Applications focused on basic and animal studies of pancreatitis or focused on pancreatic cancer will not be considered responsive to this NOFO.